G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment

Background Current immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibody-dependent cellular cytotoxicity (ADCC), a proc...

Full description

Bibliographic Details
Main Authors: Taco W Kuijpers, Timo K van den Berg, Paula Martinez Sanz, Dieke J van Rees, Lieke M J van Zogchel, Bart Klein, Panagiota Bouti, Hugo Olsman, Karin Schornagel, Ivana Kok, Ali Sunak, Kira Leeuwenburg, Ilse Timmerman, Miranda P Dierselhuis, Waleed M Kholosy, Jan J Molenaar, Robin van Bruggen, Hanke L Matlung, Godelieve A M Tytgat, Katka Franke
Format: Article
Language:English
Published: BMJ Publishing Group 2021-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/5/e002259.full

Internet

https://jitc.bmj.com/content/9/5/e002259.full

Similar Items